La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Amryt Pharma Performance dei guadagni passati
Il passato criteri di controllo 0/6
Amryt Pharma has been growing earnings at an average annual rate of 34.4%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 32.7% per year.
Informazioni chiave
34.4%
Tasso di crescita degli utili
59.1%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 6.0% |
| Tasso di crescita dei ricavi | 32.7% |
| Rendimento del capitale proprio | -0.2% |
| Margine netto | -0.3% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2022 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU
Oct 18Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval
Sep 16Amryt gets British marketing approval & orphan drug designation for rare skin disease gel
Sep 08Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition
Jul 14Amryt's Filsuvez gets approval in EU to treat rare skin disorder
Jun 23Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions
Dec 09Chiasma surges on merger agreement with Amryt
May 05Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept
Feb 04Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder
Dec 23Amryt Group's Lojuxta receives marketing approval in Brazil
Dec 09Ripartizione dei ricavi e delle spese
Come Amryt Pharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 22 | 244 | -1 | 124 | 38 |
| 30 Jun 22 | 239 | 3 | 119 | 41 |
| 31 Mar 22 | 233 | 3 | 112 | 39 |
| 31 Dec 21 | 223 | 1 | 100 | 38 |
| 30 Sep 21 | 210 | -88 | 90 | 34 |
| 30 Jun 21 | 203 | -81 | 83 | 30 |
| 31 Mar 21 | 186 | -92 | 82 | 28 |
| 31 Dec 20 | 183 | -105 | 81 | 28 |
| 30 Sep 20 | 180 | -87 | 80 | 31 |
| 30 Jun 20 | 140 | -92 | 68 | 26 |
| 31 Mar 20 | 98 | -87 | 52 | 23 |
| 31 Dec 19 | 58 | -63 | 36 | 16 |
| 31 Dec 18 | 17 | -30 | 18 | 11 |
Guadagni di qualità: AMYT is currently unprofitable.
Margine di profitto in crescita: AMYT is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: AMYT is unprofitable, but has reduced losses over the past 5 years at a rate of 34.4% per year.
Accelerare la crescita: Unable to compare AMYT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: AMYT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Rendimento del capitale proprio
ROE elevato: AMYT has a negative Return on Equity (-0.24%), as it is currently unprofitable.